October 2026 - Page 2 of 2 - Treasured Hands Home Health Agency

AstraZeneca Seeks FDA Approval for Savolitinib Plus Tagrisso in Lung Cancer That Resists Tagrisso Through MET Changes

by | Oct 1, 2026 | Uncategorized

AstraZeneca has filed for FDA approval of savolitinib plus Tagrisso for EGFR-mutated lung cancer with MET-driven resistance. Full SAFFRON data are pending.

Families of Children with Allan-Herndon-Dudley Syndrome Get a First FDA-Approved Drug, but It Does Not Treat Brain Effects

by | Oct 1, 2026 | Uncategorized

The FDA approved Emcitate, the first drug for MCT8 deficiency. It lowers excess thyroid hormone but does not treat brain effects. What parents should know.

Merck Stops Selling Recarbrio in the U.S., Leaving Hospitals with Fewer Options for Drug-Resistant Pneumonia and Infections

by | Oct 1, 2026 | Uncategorized

Merck has discontinued Recarbrio, a reserve IV antibiotic for resistant hospital infections, in the U.S. Here is what patients and families should know.

Foundayo Pill Edged Higher-Dose Oral Semaglutide on Weight and A1C in Lilly’s Indirect Type 2 Diabetes Analysis

by | Oct 1, 2026 | Uncategorized

Lilly’s indirect analysis found Foundayo 17.2 mg edged oral semaglutide 25 mg on weight and A1C in type 2 diabetes, but the gaps were modest.

Next Entries »

AstraZeneca Seeks FDA Approval for Savolitinib Plus Tagrisso in Lung Cancer That Resists Tagrisso Through MET Changes

Families of Children with Allan-Herndon-Dudley Syndrome Get a First FDA-Approved Drug, but It Does Not Treat Brain Effects

Merck Stops Selling Recarbrio in the U.S., Leaving Hospitals with Fewer Options for Drug-Resistant Pneumonia and Infections

Foundayo Pill Edged Higher-Dose Oral Semaglutide on Weight and A1C in Lilly’s Indirect Type 2 Diabetes Analysis

Recent Posts

Recent Comments

Archives

Categories

Meta

Have A Referral?